Amida Care Statement on U.S. House of Representatives Oversight Committee Hearing on PrEP Pricing and Access
(New York, NY – May 20, 2019) – The following is a statement from Amida Care on the May 16 House of Representatives Oversight Committee hearing on pricing and access as it relates to pre-exposure prophylaxis (PrEP):